Cabaletta Bio, Inc.
CABA · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.03 | 0.00 | -0.04 | -0.28 |
| FCF Yield | -14.45% | -32.52% | -45.89% | -20.65% |
| EV / EBITDA | -4.66 | 0.60 | 0.97 | 1.48 |
| Quality | ||||
| ROIC | -28.19% | -22.57% | -24.70% | -19.66% |
| Gross Margin | 0.00% | 0.00% | 0.00% | 50.00% |
| Cash Conversion Ratio | 0.77 | 0.67 | 0.86 | 0.71 |
| Growth | ||||
| Revenue 3-Year CAGR | -100.00% | -100.00% | -100.00% | -100.00% |
| Free Cash Flow Growth | -13.08% | 3.17% | -34.42% | -14.20% |
| Safety | ||||
| Net Debt / EBITDA | 0.78 | 2.74 | 2.93 | 6.37 |
| Interest Coverage | -79.77 | -80.40 | -126.31 | -45.17 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | -2,156.61 | -1,383.27 | -1,204.70 | -540.99 |